# Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer

> **NCT01186731** · PHASE2 · COMPLETED · sponsor: **INSYS Therapeutics Inc** · enrollment: 40 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Liposome Entrapped Docetaxel (LE-DT)

## Key facts

- **NCT ID:** NCT01186731
- **Lead sponsor:** INSYS Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-04
- **Final completion:** 2011-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2012-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01186731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01186731, "Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01186731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*